Primary Care Clinics in Stanton, CA Accepting Medicare
10 Primary Care Clinics found. Showing 1 - 10
 Advanced Hyperbarics Rx Clinic/Center Medicare: Not Enrolled in Medicare Practice Location: 7499 Cerritos Ave, Stanton, CA 90680 Phone: 714-527-4000 Fax: 714-527-4002 |
Central City Community Health Center Clinic/Center - Federally Qualified Health Center (FQHC) Medicare: Medicare Enrolled Practice Location: 12116 Beach Blvd, Stanton, CA 90680 Phone: 714-898-2222 Fax: 714-894-9865 |
Pueblo Medical Center Inc Clinic/Center Medicare: Medicare Enrolled Practice Location: 8045 Cerritos Ave, Stanton, CA 90680 Phone: 714-828-2444 Fax: 714-816-0529 |
Us Medical Center Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 12679 Beach Blvd, Stanton, CA 90680 Phone: 714-379-8400 |
Life Hyperbarics Clinic/Center Medicare: Not Enrolled in Medicare Practice Location: 7499 Cerritos Ave, Stanton, CA 90680 Phone: 714-527-4000 Fax: 714-710-8287 |
Dean Tran, D.o., Inc Clinic/Center - Primary Care Medicare: Not Enrolled in Medicare Practice Location: 11418 1/2 Renaissance Way, Stanton, CA 90680 Phone: 714-606-3502 |
Stacey Qt Le, Od Professional Optometry Corporation Clinic/Center Medicare: Not Enrolled in Medicare Practice Location: 7038 Katella Ave, Stanton, CA 90680 Phone: 714-895-4899 |
Nn Medical, Inc. Family Medicine Medicare: Medicare Enrolled Practice Location: 12680 Beach Blvd, Suite G, Stanton, CA 90680 Phone: 714-903-1920 |
Livingstone Community Health Clinic Clinic/Center - Community Health Medicare: Medicare Enrolled Practice Location: 12362 Beach Blvd Ste 10, Stanton, CA 90680 Phone: 714-248-9500 Fax: 714-622-4943 |
Clinica Medica San Blas General Practice Medicare: Not Enrolled in Medicare Practice Location: 7777 Katella Avenue, Stanton, CA 90680 Phone: 714-220-2223 Fax: 714-220-2249 |
News Archive
Combination of cetuximab and cisplatin chemotherapy benefits women with triple-negative breast cancer
European researchers have proven for the first time that targeting the epidermal growth factor receptor can provide substantial clinical benefit for women with hard-to-treat triple-negative breast cancer.
Celgene's first-quarter non-GAAP total revenue up 31% to $789 million
Celgene Corporation announced non-GAAP net income of $294.6 million, or non-GAAP diluted earnings per share of $0.63 for the quarter ended March 31, 2010. Non-GAAP net income for the first quarter of 2009 was $205.1 million or non-GAAP diluted earnings per share of $0.44. Based on U.S. GAAP, Celgene reported net income of $234.4 million, or diluted earnings per share of $0.50 for the quarter ended March 31, 2010. GAAP net income for the first quarter of 2009 was $162.9 million, or diluted earnings per share of $0.35.
Breastfeeding support lacking in U.S. hospitals and birth centers
Many birth facilities in the United States are not providing maternity care that is fully supportive of breastfeeding, according to a study in today's Morbidity and Mortality Weekly Reports (MMWR), a publication of the Centers for Disease Control and Prevention.
Tracking patients' medical records over time reveals more about diseases
Electronic health records contain important information about patients' health outlook and the care they receive, but the records are not always precise.
Talazoparib did not show overall survival benefit in patients with advanced BRCA-mutated breast cancer
New data from the Phase III EMBRACA trial led by researchers at The University of Texas MD Anderson Cancer Center found the PARP inhibitor talazoparib did not demonstrate a statistically significant overall survival (OS) benefit for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
› Verified 2 days ago